|Systematic (IUPAC) name|
|Licence data||US FDA:|
|14px (what is this?)|
Regadenoson (INN, code named CVT-3146) is an A2A adenosine receptor agonist that is a coronary vasodilator. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging.
In The Pharmacologic Stress Test , Regadenoson (besides other agents) is used to stress the heart to the degree it would be stressed during exercise and assess for ischemic changes (ST depressions or elevations on ECG).
It was approved by the United States Food and Drug Administration on April 10, 2008 and is marketed by Astellas Pharma under the tradename Lexiscan. It is approved for use in the European Union and under the name of Rapiscan. It is currently being marketed by GE Healthcare and is being sold in both the United Kingdom and Germany.
Regadenoson has a 2- to 3-minute biological half-life, as compared with adenosine's 30-second half-life. Regadenoson stress protocols using a single bolus have been developed, obviating the need for a 4-6 minute continuous infusion. Another difference is that adenosine infusion is weight based (140mcg/Kg/minute) and with regadenoson the 0.4mg/5mL preloaded syringe dose is standard for all weights. Regadenoson stress tests are not affected by the presence of beta blockers, as regadenoson vasodilates but does not stimulate beta adrenergic receptors.
- Cerqueira MD (July 2004). "The future of pharmacologic stress: selective A2A adenosine receptor agonists". Am. J. Cardiol. 94 (2A): 33D–40D; discussion 40D–42D. PMID 15261132. doi:10.1016/j.amjcard.2004.04.017.
- CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM)
Lua error in package.lua at line 80: module 'Module:Buffer' not found.